Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Por Park, Haeseong, Garrido-Laguna, Ignacio, Naing, Aung, Fu, Siqing, Falchook, Gerald S., Piha-Paul, Sarina A., Wheler, Jennifer J., Hong, David S., Tsimberidou, Apostolia M., Subbiah, Vivek, Zinner, Ralph G., Kaseb, Ahmed O., Patel, Shreyaskumar, Fanale, Michelle A., Velez-Bravo, Vivianne M., Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip
Publicado no Oncotarget (2016)